Infectious Diseases (INF)

EP-004 - A SINGLE CENTRE, PROSPECTIVE STUDY TO EVALUATE THE EFFECT OF DOUBLE CARBAPENEM BASED COLISTIN THERAPY VERSUS BEST AVAILABLE THERAPY FOR THE TREATMENT OF CARBAPENEM RESISTANT ENTEROBACTERIACEAE AT A TERTIARY CARE HOSPITAL IN INDIA.

PT-012 - POPULATION PHARMACOKINETICS OF ISONIAZID IN TBTC STUDY 31/ACTG A5349.

EP-027 - EXAMINING THE REGIONAL IMPACT OF FENTANYL ON INFLAMMATORY MEDIATORS WITHIN THE BRAIN IN THE SETTING OF HIV.

LB-004 - MOLNUPIRAVIR EXPOSURE-RESPONSE OF CLINICAL OUTCOMES IN TREATMENT OF COVID-19.

LB-005 - MOLNUPIRAVIR EXPOSURE-RESPONSE RELATIONSHIPS FOR CLINICAL OUTCOMES, VIROLOGY, AND MECHANISM OF ACTION BIOMARKERS ARE CONSISTENT IN TREATMENT OF COVID-19.

PI-006 - PHARMACOKINETICS AND SAFETY OF SINGLE-DOSE BEPIROVERSIN IN ADULTS WITH MODERATE HEPATIC IMPAIRMENT AND HEALTHY MATCHED CONTROLS (B-ASSURED).

PI-007 - PHARMACOKINETICS OF REMDESIVIR AND ITS METABOLITES IN PARTICIPANTS WITH MODERATE AND SEVERE HEPATIC IMPAIRMENT.

PI-008 - POPULATION MODELING OF GSK3036656 PHARMACOKINETICS AND EARLY BACTERICIDAL ACTIVITY.

PII-021 - QUANTIFYING THE EFFECTS OF ALCOHOL USE ON DRIED BLOOD SPOT CONCENTRATIONS OF SOFOSBUVIR’S ACTIVE METABOLITE, 007-TP, IN PERSONS WITH HEPATITIS C USING PHOSPHATIDYLETHANOL AS AN OBJECTIVE BIOMARKER OF ALCOHOL CONSUMPTION.

PII-022 - RIFAPENTINE EXPOSURE-RESPONSE RELATIONSHIPS ARE DIFFERENT FOR PHASE II AND PHASE III PRIMARY EFFICACY ENDPOINTS IN TUBERCULOSIS CLINICAL TRIALS.

PII-023 - RISK OF QT PROLONGATION WITH OLIGONUCLEOTIDES: A REVIEW OF PUBLISHED EVIDENCE.

PII-024 - TRANSLATIONAL MODEL-BASED META-ANALYSIS - A POWERFUL QUANTITATIVE TOOL IN DEVELOPING VACCINES AGAINST SARS-COV-2 VARIANTS.